Heart disease prevention drug fails at final hurdle

The pharmaceutical company closest to getting a drug to market to reduce Lipoprotein (a) levels announced that while it reduces levels of these molecules, that didn’t translate into fewer cardiovascular events.

What does this mean for those with high Lp (a)?

Guest/s

Dr Nelson Wang, cardiologist and senior research fellow, George Institute of Public Health

References

Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)